Quick Answer
Milestone Pharmaceuticals Inc. reported Long-Term Debt of $57.19 million for fiscal year 2025.
Milestone Pharmaceuticals Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $57.19M | +7.2% |
| 2024 | $53.35M | +7.2% |
| 2023 | $49.77M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $56.21M | +7.2% | +1.8% |
| June 30, 2025 | $55.24M | +7.2% | +1.8% |
| March 31, 2025 | $54.29M | +7.2% | +1.8% |
| December 31, 2024 | $53.35M | +7.2% | +1.8% |
| September 30, 2024 | $52.43M | +7.2% | +1.8% |
| June 30, 2024 | $51.53M | +7.2% | +1.8% |
| March 31, 2024 | $50.64M | +7.0% | +1.8% |
| December 31, 2023 | $49.77M | — | +1.8% |
- Milestone Pharmaceuticals Inc. showed an increase of +7.2% in Long-Term Debt compared to the prior fiscal year.
- Over the 2023–2025 period, Milestone Pharmaceuticals Inc.’s long-term debt has grown by 14.9% (from $49.77 million to $57.19 million).
- The most recent figure is from Milestone Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: